A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Study Summary

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Conditions

Multiple Myeloma

Interventions / Drugs

BMS-986393 Alnuctamab Mezigdomide Iberdomide Elranatamab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment147 participants

Primary Completion—

Lead SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

Data Retrieved2026-04-11 04:08:14.746591+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.